14 Stocks With Heavy Insider Buying In 2024
In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets...
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
| 11.93 | |
| 12.07 | |
| - | |
| 12.3 | |
| 11.77 | |
| 4.26-16.9 | |
| 656 M | |
| 54 913 K | |
| 0 | |
| -0.38 | |
| 0.736 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets...
Altium Capital Management LP, a New York-based investment firm, recently made a significant move in the stock market by acquiring a new stake in Alimera Sciences Inc. This article provides an in-depth...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: